|
ARHGEF11 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.49309999994707E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.89890000004789E-06 |
| Normal-vs-Stage2 |
4.858200E-01 |
| Normal-vs-Stage3 |
4.96520000003997E-07 |
| Normal-vs-Stage4 |
2.15130000003061E-06 |
| Stage1-vs-Stage2 |
5.728400E-02 |
| Stage1-vs-Stage3 |
2.034000E-01 |
| Stage1-vs-Stage4 |
1.500200E-01 |
| Stage2-vs-Stage3 |
1.824390E-02 |
| Stage2-vs-Stage4 |
1.456210E-02 |
| Stage3-vs-Stage4 |
7.990800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.65379999999794E-05 |
| Normal-vs-AfricanAmerican |
8.120400E-03 |
| Normal-vs-Asian |
6.44519999999371E-05 |
| Caucasian-vs-AfricanAmerican |
4.532200E-01 |
| Caucasian-vs-Asian |
5.301000E-01 |
| AfricanAmerican-vs-Asian |
2.821600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.696700E-03 |
| Normal-vs-Female |
2.03659999975514E-08 |
| Male-vs-Female |
1.420600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.54089999999663E-05 |
| Normal-vs-Age(41-60Yrs) |
4.67680000004744E-06 |
| Normal-vs-Age(61-80Yrs) |
4.838200E-03 |
| Normal-vs-Age(81-100Yrs) |
4.351500E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.758000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.956000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.944800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.815800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.195800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.440400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.66891999999752E-05 |
| Classical-VS-Follicular |
5.575200E-01 |
| Classical-VS-Other |
7.869600E-01 |
| Classical-VS-Normal |
3.365000E-04 |
| Tall-VS-Follicular |
6.593200E-04 |
| Tall-VS-Other |
8.282200E-02 |
| Tall-VS-Normal |
2.18459994538733E-09 |
| Follicular-VS-Other |
9.311600E-01 |
| Follicular-VS-Normal |
2.033600E-04 |
| Other-VS-Normal |
8.752500E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.192100E-04 |
| Normal-vs-N1 |
3.08559999995239E-07 |
| N0-vs-N1 |
1.868080E-02 |
|
|
